[Local injection of bevacizumab for treatment of primary active pterygium]

To report subconjunctival injection of bevacizumab [Avastin] for treatment of primary active pterygium. Patients with primary active pterygia without other ocular disease, pregnancy or diabetes mellitus were enrolled. Patients were randomly allocated into two groups to receive injection of Avastin or placebo. Patients were evaluated for changes in photophobia, conjunctival congestion and size of the pterygium. In the first 48 hours, conjunctival congestion was greater in the treatment group as compared to the placebo group [125.76 vs 73.98, P<0.001]. The same was observed for photophobia [139.01 vs 69.18, P<0.001], but there was no difference in the size of pterygium between the two groups [105.86 vs 94.08, P= 0.130]. After one week, conjunctival congestion [90.98 vs 108.20, P= 0.01] and photophobia [85.08 vs 114.36 P<0.001] were less marked in the treatment group; however, mean pterygium size did not differ between the two groups [105.89 vs 94.06, P= 0.120]. This trend continued up to 6 months after the injection, the time at which the results regressed to become similar to those observed 48 hours after injection. Local injection of bevacizumab may be effective in treatment of pterygium; however, repeat injections should be considered

In-vitro susceptibility of infective keratitis causative bacteria to topical povidone iodine

Purpose: To evaluate the in-vitro susceptibility of bacterial isolates from the cases of corneal ulcer to povidone iodine. Setting: Department of ophthalmology, and clinical microbiology research center, Shiraz University of Medical Sciences, Shiraz, Iran. Patients and The in-vitro susceptibility and Minimum Inhibitory Concentration [MIC] of the bacteria isolated from the cornea of 50 cases of bacterial corneal ulcer to povidone iodine was determined by broth dilution method. Concentrations of 1%, 2%, 5% and 10% of povidone iodine were tested. Bacterial isolates included 50% S. epidermidis, 20% P. aerogenosa, 10% S. aureus, 4% Acintobacter, 4% S. pneumoniae, 4% E-coli, 2% Proteous, 2% S. viridance, 2% Diphtheroid and 2% Bacillous. Povidone iodine bactericidal efficacy for gram positive bacteria was at least 82.36%, 91.2%, 100% and 100% in 1%, 2%, 5% and 10% concentrations after 5 minutes exposure time. The bactericidal efficacy of this agent over the gram negative bacteria was at least 62.5%, 87.5%, 100% and 100% in 1%, 2%, 5% and 10% concentrations after 5 minutes exposure time, respectively. Povidone iodine was shown to have a broad spectrum in- vitro bactericidal efficacy in cases of bacterial keratitis. If further invivo studies confirm the efficacy of this agent over the bacterial keratitis, it would be suggested as a broad spectrum medication for the treatment of these cases